Literature DB >> 29754581

The clinical characteristics and therapy response of patients with acquired pure red cell aplasia.

Rong Fu1, Tian Zhang1, Bingnan Liu1, Jia Song1, Guojin Wang1, Lijuan Li1, Huaquan Wang1, Limin Xing1, Yuhong Wu1, Jing Guan1, Zonghong Shao1.   

Abstract

OBJECTIVE: To summarize the clinical characteristics of acquired pure red cell aplasia (PRCA) patients diagnosed in our hospital in the last 10 years.
METHOD: The clinical features, immune state and treatment response of acquired PRCA patients diagnosed in our hospital from January 2007 to January 2017 were retrospectively analyzed.
RESULTS: The results showed that thymoma (13.21%) and parvovirus B19 (11.32%) were the most common causes for secondary PRCA. Ferritin (Fer) levels and erythropoietin (EPO) levels were increased in PRCA patients. The total CR and PR rate of immunosuppressive therapy in our studies was 68.29% and 12.20%, respectively. Patients with EPO level >400 U/L and Fer level >200 ng/ml had significantly lower CR rate than others. The patients with EPO level >400 U/L also had longer hemoglobin recovery time than patients with EPO level ≤400 U/L. Patients treated with corticosteroids (CS) + cyclosporine A (CsA) had lower relapse rate compared to the CS group (29.17% vs. 80.00%, P < .05).
CONCLUSION: Our data showed that patients with PRCA had high EPO and Fer levels. Thymoma and viral infections are the most common causes for secondary PRCA. The CS+ CsA group had lower relapse rate than CS group although response rate was similar. Increased EPO and Fer levels might be the negative factors for prognosis of acquired PRCA.

Entities:  

Keywords:  Pure red cell aplasia; idiopathic PRCA; immunosuppressive therapy; secondary PRCA

Mesh:

Substances:

Year:  2018        PMID: 29754581     DOI: 10.1080/10245332.2018.1470068

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  3 in total

1.  How I manage acquired pure red cell aplasia in adults.

Authors:  Carmelo Gurnari; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2021-04-15       Impact factor: 22.113

Review 2.  Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs.

Authors:  Candida Vitale; Maria Chiara Montalbano; Chiara Salvetti; Elia Boccellato; Valentina Griggio; Mario Boccadoro; Marta Coscia
Journal:  Cancers (Basel)       Date:  2020-01-23       Impact factor: 6.639

3.  [Evaluation of the efficacy and safety of recombined human erythropoietin combined with cyclosporin A in the treatment of patients with pure red cell aplasia].

Authors:  Z S Chen; C Yang; M Chen; B Han
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-11-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.